灌裝-完成製藥合約製造市場- 副產品（西林瓶[玻璃、塑膠]、預裝注射器、藥筒）、分子（大分子和小分子）、最終用途（生物製藥和製藥公司）、全球預測（2024 - 2032）

受製藥公司為簡化生產流程和降低營運成本而日益成長的外包趨勢的推動，2024年至2032年，灌裝藥品合約製造市場規模的複合年成長率將達到6.2%。例如，2024 年 3 月，SMC Ltd. 收購了位於北卡羅來納州夏洛特的一家灌裝/加工工廠，以透過實驗室到市場開發、設備製造和二次包裝擴大為製藥客戶提供的服務。

配備先進技術和設施的合約製造商確保遵守嚴格的品質標準並遵守監管指南，包括良好生產規範 (GMP)。這種能力對於滿足全球對高品質藥品日益成長的需求以及應對複雜的國際市場也至關重要。

整個產業分為產品、分子、最終用途和區域。

從產品來看，由於對方便、安全的給藥系統的需求不斷成長，預充式注射器領域的灌裝藥品合約製造市場預計將成長到 2032 年。預充式注射器具有精確的劑量傳遞、降低污染風險和易於給藥等優點，使其受到醫療保健提供者和患者的歡迎。專門從事灌裝-完成服務的合約製造商也透過提供預灌封注射器無菌填充、組裝和包裝方面的專業知識來幫助滿足這些需求。

就最終用途而言，製藥公司領域的灌裝醫藥合約製造市場將在 2024 年至 2032 年間錄得顯著成長，這將受到外包的青睞，以提高營運效率並專注於核心競爭力。製藥公司越來越依賴 CMO 提供填充完成服務，以簡化生產、縮短上市時間並有效管理成本。合約製造進一步為製藥公司提供了無菌灌裝、包裝和監管合規的專業知識，有利於該細分市場的成長。

在醫療保健支出增加、人口成長和慢性病盛行率上升的推動下，預計到 2032 年，亞太地區灌裝醫藥合約製造業規模將以驚人的速度成長。戰略地理位置和基礎設施的改善有利於更容易進入全球主要市場，從而增強在國際舞台上的競爭力。製藥公司也不斷擴大業務並投資創新藥物配方，刺激了區域市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 醫藥外包趨勢日益明顯
    • 填充加工製造流程不斷進步的技術
    • 藥物配方的複雜性不斷增加
  • 產業陷阱與挑戰
    • 嚴格的監管問題
    • 來自內部製造的競爭
• 成長潛力分析
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

• 主要趨勢
• 小瓶
  • 玻璃瓶
  • 塑膠瓶
• 預充式注射器 (PFS)
  • 玻璃PFS
  • 塑膠PFS
• 墨水匣
• 其他產品

第 6 章：市場估計與預測：按分子，2021 - 2032

• 主要趨勢
• 大分子
• 小分子

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 生物製藥公司
• 製藥公司

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Boehringer Ingelheim International GmbH
• Catalent Inc.
• Eurofins Scientific
• Fresenius Kabi Contract Manufacturing
• MabPlex International Co. Ltd.
• Novartis AG
• Recipharm AB
• Societal CDMO
• Simtra BioPharma Solutions (Baxter International Inc.)
• Symbiosis Pharmaceutical Services

Fill-finish pharmaceutical contract manufacturing market size will depict 6.2% CAGR from 2024 to 2032, driven by the increasing outsourcing trend among pharmaceutical companies to streamline production processes and reduce operational costs. For instance, in March 2024, SMC Ltd. acquired a fill/finish facility in Charlotte, NC, for expanding services to pharma clients with lab-to-market development, device manufacture, and secondary packaging.

Contract manufacturers equipped with advanced technologies and facilities are ensuring adherence to stringent quality standards and compliance with regulatory guidelines, including Good Manufacturing Practices (GMP). This capability is also essential for meeting the increasing global demand for high-quality pharmaceutical products while navigating the complexities of international markets.

The overall industry is segmented into product, molecule, end-use and region.

Based on product, the fill-finish pharmaceutical contract manufacturing market from the prefilled syringes segment is set to grow up to 2032 due to the increasing demand for convenient and safe drug delivery systems. Prefilled syringes offer advantages, such as precise dosage delivery, reduced risk of contamination, and ease of administration, making them popular among healthcare providers and patients. Contract manufacturers specializing in fill-finish services also help in meeting these demands by providing expertise in sterile filling, assembly, and packaging of prefilled syringes.

With respect to end use, the fill-finish pharmaceutical contract manufacturing market from the pharmaceutical companies segment will record a notable growth rate between 2024 and 2032 favored by outsourcing to enhance operational efficiency and focus on core competencies. Pharmaceutical firms are increasingly relying on CMOs for fill-finish services to streamline production, reduce time-to-market, and manage costs effectively. Contract manufacturing further offers pharmaceutical companies access to specialized expertise in sterile filling, packaging, and regulatory compliance, favoring the segment growth.

Asia Pacific fill-finish pharmaceutical contract manufacturing industry size is anticipated to grow at an impressive pace through 2032 fueled by increasing healthcare expenditure, growing population, and the rising prevalence of chronic diseases. The strategic geographical location and infrastructure improvements are facilitating easier access to key global markets for enhancing the competitiveness on international stage. Pharmaceutical companies are also continuing to expand their operations and invest in innovative drug formulations, subsequently stimulating the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing trend of pharmaceutical outsourcing
    • 3.2.1.2 Rising technological advancements in fill-finish manufacturing processes
    • 3.2.1.3 Increasing complexity of drug formulations
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory issues
    • 3.2.2.2 Competition from in-house manufacturing
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Vials
  • 5.2.1 Glass vials
  • 5.2.2 Plastic vials
• 5.3 Prefilled syringes (PFS)
  • 5.3.1 Glass PFS
  • 5.3.2 Plastic PFS
• 5.4 Cartridges
• 5.5 Other products

Chapter 6 Market Estimates and Forecast, By Molecule, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Large molecules
• 6.3 Small molecules

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Biopharmaceutical companies
• 7.3 Pharmaceutical companies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Boehringer Ingelheim International GmbH
• 9.2 Catalent Inc.
• 9.3 Eurofins Scientific
• 9.4 Fresenius Kabi Contract Manufacturing
• 9.5 MabPlex International Co. Ltd.
• 9.6 Novartis AG
• 9.7 Recipharm AB
• 9.8 Societal CDMO
• 9.9 Simtra BioPharma Solutions (Baxter International Inc.)
• 9.10 Symbiosis Pharmaceutical Services